Nieweglowska Dorota, Hajdyla-Banas Iwona, Pitynski Kazimierz, Banas Tomasz, Grabowska Oliwia, Juszczyk Grzegorz, Ludwin Artur, Jach Robert
Department of Gynecology and Oncology, Jagiellonian University, Chair of Gynecology and Obstetrics, Krakow, 21 Kopernika Str, 30-501, Krakow, Poland.
Center of Rheumatology, Immunology and Rehabilitation, Dietl Specialistic Hospital, Krakow, Poland.
Reprod Biol Endocrinol. 2015 Nov 24;13:128. doi: 10.1186/s12958-015-0125-x.
Endometriosis is a well-known cause of infertility, and the anti-Mullerian hormone (AMH) is an accepted biomarker of ovarian reserve and response to artificial reproductive technology procedures. The present study was a prospective analysis of age-dependent AMH serum concentration in women with bilateral and unilateral ovarian endometriomas before therapy onset compared with healthy controls.
This prospective cross-sectional study included 384 women aged 18-48 years. AMH serum concentration was assessed between days 3 and 6 of the menstrual cycle in 78 patients with bilateral and 157 patients with unilateral ovarian endometriomas and compared with 149 healthy controls. Ovarian endometriosis was confirmed histopathologically, and data were presented as medians with interquartile range (IQR).
Stage III endometriosis was diagnosed in 53.2 %, stage IV in 18.3 %, stage V in 23.4 % and stage VI in 5.4 % of the patients. Patients with bilateral ovarian endometriomas showed the lowest median AMH levels compared with patients suffering from unilateral ovarian endometriosis (0.55; IQR: 0.59 vs. 2.00; IQR: 2.80; p < 0.001) and the control group (0.55; IQR: 0.59 vs. 2.84; IQR: 3.2; p < 0.001). Median AMH concentration values were not significantly different between patients with unilateral ovarian endometriosis and the healthy controls (2.00; IQR: 2.80 vs. 2.84; IQR: 3.2; p = 0.182). A strongly negative correlation between AMH levels and age was confirmed in healthy individuals (R = -0.834; p < 0.001) and women with unilateral ovarian endometriomas (R = -0.774; p < 0.001). Patients with bilateral ovarian endometriosis showed a significantly negative but only moderate correlation between AMH levels and age (R = -0.633; p < 0.001), which was significantly lower than in the healthy controls (R = -0.633 vs. R = -0.834; p = 0.006) but not in the patients with unilateral ovarian endometriosis (R = -0.663 vs. R-0.774; p = 0.093). Based on a multivariate regression analysis, only bilateral localization of ovarian endometrial cysts (p = 0.003) and patient age (p < 0.001), but not left/right localization of unilateral cyst or cyst volume, were negatively associated with AMH serum concentration.
According to our data, unilateral ovarian endometriosis had a moderately negative and nonsignificant effect on AMH-based ovarian reserve evaluated prior to surgery, irrespective of age. In contrast, the ovarian reserve was significantly reduced in women with bilateral ovarian endometriomas.
子宫内膜异位症是导致不孕的一个众所周知的原因,抗苗勒管激素(AMH)是公认的卵巢储备及对辅助生殖技术治疗反应的生物标志物。本研究对双侧和单侧卵巢子宫内膜异位囊肿患者治疗开始前与健康对照相比的年龄依赖性血清AMH浓度进行了前瞻性分析。
这项前瞻性横断面研究纳入了384名年龄在18至48岁之间的女性。在月经周期的第3至6天评估了78例双侧卵巢子宫内膜异位囊肿患者和157例单侧卵巢子宫内膜异位囊肿患者的血清AMH浓度,并与149名健康对照进行比较。卵巢子宫内膜异位症经组织病理学确诊,数据以中位数及四分位数间距(IQR)表示。
53.2%的患者诊断为III期子宫内膜异位症,18.3%为IV期,23.4%为V期,5.4%为VI期。与单侧卵巢子宫内膜异位症患者(0.55;IQR:0.59 vs. 2.00;IQR:2.80;p<0.001)和对照组(0.55;IQR:0.59 vs. 2.84;IQR:3.2;p<0.001)相比,双侧卵巢子宫内膜异位囊肿患者的血清AMH中位数水平最低。单侧卵巢子宫内膜异位症患者与健康对照之间的AMH浓度中位数无显著差异(2.00;IQR:2.80 vs. 2.84;IQR:3.2;p = 0.182)。在健康个体(R = -0.834;p<0.001)和单侧卵巢子宫内膜异位症女性(R = -0.774;p<0.001)中证实AMH水平与年龄呈强负相关。双侧卵巢子宫内膜异位症患者的AMH水平与年龄呈显著负相关,但仅为中度相关(R = -0.633;p<0.001),这显著低于健康对照(R = -0.633 vs. R = -0.834;p = 0.006),但与单侧卵巢子宫内膜异位症患者相比无显著差异(R = -0.663 vs. R-0.774;p = 0.093)。基于多因素回归分析,仅卵巢子宫内膜囊肿的双侧定位(p = 0.003)和患者年龄(p<0.001)与AMH血清浓度呈负相关,而单侧囊肿的左右定位或囊肿体积与AMH血清浓度无关。
根据我们的数据,单侧卵巢子宫内膜异位症对术前基于AMH评估卵巢储备有中度负面且无显著影响,与年龄无关。相比之下,双侧卵巢子宫内膜异位囊肿女性的卵巢储备显著降低。